Merck & Co., Inc. Deferred Tax Liabilities, Gross
Merck & Co., Inc. (MRK) had Deferred Tax Liabilities, Gross of $5.57 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-24
- 2025-12-31: Deferred Tax Liabilities, Gross $5.57B.
- 2024-12-31: Deferred Tax Liabilities, Gross $3.06B.
- 2023-12-31: Deferred Tax Liabilities, Gross $2.96B; Deferred Tax Liabilities, Gross as first filed $2.84B.
- 2022-12-31: Deferred Tax Liabilities, Gross $4.31B; Deferred Tax Liabilities, Gross as first filed $4.30B.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $5.57B 10-K · filed 2026-02-24 | |
| 2024-12-31 | $3.06B 10-K · filed 2026-02-24 | |
| 2023-12-31 | $2.96B 10-K · filed 2025-02-25 | $2.84B 10-K · filed 2024-02-26 |
| 2022-12-31 | $4.31B 10-K · filed 2024-02-26 | $4.30B 10-K · filed 2023-02-24 |
| 2021-12-31 | $5.02B 10-K · filed 2023-02-24 | $4.75B 10-K · filed 2022-02-25 |
| 2020-12-31 | $2.66B 10-K · filed 2022-02-25 | $2.68B 10-K · filed 2021-02-25 |
| 2019-12-31 | $3.00B 10-K · filed 2021-02-25 | |
| 2018-12-31 | $2.82B 10-K · filed 2020-02-26 | |
| 2017-12-31 | $3.64B 10-K · filed 2019-02-27 | $3.82B 10-K · filed 2018-02-27 |
| 2016-12-31 | $7.64B 10-K · filed 2018-02-27 | $7.52B 10-K · filed 2017-02-28 |
| 2015-12-31 | $8.88B 10-K · filed 2017-02-28 | |
| 2014-12-31 | $7.19B 10-K · filed 2016-02-26 | |
| 2013-12-31 | $9.11B 10-K · filed 2015-02-27 | |
| 2012-12-31 | $9.51B 10-K · filed 2014-02-27 | |
| 2011-12-31 | $9.85B 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |